---
document_datetime: 2025-09-12 16:04:16
document_pages: 6
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/livmarli-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: livmarli-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 4.3754121
conversion_datetime: 2025-12-30 13:01:49.868277
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Livmarli

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                     | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                                                                                                                                                                                                                                                                                          |
|----------------------|-----------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| S/0019               | 2nd annual re-assessment.                                 | 24/07/2025                          | 28/08/2025                                  | Annex II                         | The CHMP, having reviewed the evidence of compliance with the specific obligations and the impact of the data submitted by the MAH on the benefit/risk profile of the medicinal product, concluded that marketing authorisation of Livmarli should be maintained. PFIC was included in SOB02 in order to ensure adequate monitoring of safety and efficacy of maralixibat in the treatment in addition to SOB01. |
| PSUSA/11032 /202409  | Periodic Safety Update EU Single assessment - maralixibat | 08/05/2025                          | n/a                                         |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| IA/0017/G           | This was an application for a group of variations. B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.II.b.3.a - Change in the manufacturing process of                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 11/12/2024   | n/a        |                                  |                                                                             |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------------|-----------------------------------------------------------------------------|
| PSUSA/11032 /202403 | Periodic Safety Update EU Single assessment - maralixibat                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 31/10/2024   | n/a        |                                  | PRAC Recommendation - maintenance                                           |
| II/0003/G           | This was an application for a group of variations. Grouped variation consisting of: Extension of indication to include treatment of Progressive Familial Intrahepatic Cholestasis (PFIC) in patients 3 months of age and older for LIVMARLI, based on results from studies MRX-502, LUM001- 501, MRX-503, MRX-800 and MRX-801; MRX-502 is an international, multicenter, randomized, double- blind, placebo-controlled, parallel group Phase 3 study that evaluated the efficacy and safety of maralixibat in PFIC participants aged >12 months to <18 years on a proposed dosage of up to 600 Î¼g/kg BID over 6 months. As a consequence, sections 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet and Annex II are updated in accordance. Version 4.1 of the RMP is agreed. In addition, the Marketing authorisation holder (MAH) took the opportunity to introduce | 30/05/2024   | 28/06/2024 | SmPC, Annex II, Labelling and PL | Please refer to Scientific Discussion 'Livmarli- EMEA/H/C/005857/II/0003/G' |

<div style=\"page-break-after: always\"></div>

|                     | minor editorial changes to the labelling. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits                                                                                                                                                    |            |            |             |                                                                                                                                                                                                                                                                   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/11032 /202309 | Periodic Safety Update EU Single assessment - maralixibat                                                                                                                                                                                                                                                                                                                                                                                                                          | 25/04/2024 | 20/06/2024 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/11032/202309.                                                                                                                        |
| S/0012              | 1st annual re-assessment.                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 25/04/2024 | n/a        |             | The CHMP, having reviewed the evidence of compliance with the specific obligations and the impact of the data submitted by the MAH on the benefit/risk profile of the medicinal product, concluded that marketing authorisation of LIVMARLI should be maintained. |
| II/0008/G           | This was an application for a group of variations. B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.1.g - Change in the specification parameters | 14/03/2024 | n/a        |             |                                                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| material/intermediate/reagent approved specs for starting which may have a significant the AS and/or the FP B.I.b.2.a - Change in test starting material/reagent/intermediate changes to an approved B.I.b.2.e - Change in test starting material/reagent/intermediate changes to a test procedure or addition) for the AS material/intermediate B.I.d.1.a.4 - Stability of period/storage period re-test period/storage data B.I.b.1.c - Change in the and/or limits of an AS, material/intermediate/reagent specification parameter corresponding test method B.I.b.1.d - Change in the and/or limits of an AS, material/intermediate/reagent significant specification an obsolete parameter) B.I.a.1.g - Change in the starting material/reagent/intermediate Introduction of a new not supported by an ASMF   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

| IA/0013             | B.II.b.4.b - Change in the batch size (including batch size ranges) of the finished product - Downscaling down to 10-fold                                                                                                                                                                                                                                                                                                                                             | 25/01/2024   | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0009             | Update of section 5.3 of the SmPC in order to update preclinical safety information based on final results from study MRX-NC-006, listed as a category 3 study in the RMP. This is a 104-week oral gavage carcinogenicity study of maralixibat in Sprague Dawley Rats performed to evaluate the toxicity and carcinogenic potential of maralixibat. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 18/01/2024   | 20/06/2024 | SmPC                   | Administration of maralixibat to rats resulted in no increases in tumour incidences in the final data of the presented study. Based on the negative outcome of the rat carcinogenicity study and the overall weight of evidence, no carcinogenic risk is anticipated for patients and chapter 5.3 SmPC has been updated accordingly. In addition, the detailed information in 5.3 of the SmPC that no effects on fertility were observed I female rats was deleted as not considered helpful for the prescriber. |
| IB/0010             | B.II.f.1.b.2 - Stability of FP - Extension of the shelf life of the finished product - After first opening (supported by real time data)                                                                                                                                                                                                                                                                                                                              | 07/12/2023   | 20/06/2024 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| IB/0007             | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                                         | 08/11/2023   | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| PSUSA/11032 /202303 | Periodic Safety Update EU Single assessment - maralixibat                                                                                                                                                                                                                                                                                                                                                                                                             | 26/10/2023   | n/a        |                        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| IAIN/0006           | C.I.11.a - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of wording agreed by the competent authority                                                                                                                                                                                                                                                                             | 04/07/2023   | 20/06/2024 | Annex II               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

| II/0002   | B.I.a.1.g - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Introduction of a new manufacturer of the AS that is not supported by an ASMF and requires significant update to the relevant AS section in the dossier                                                                                     | 15/06/2023   | n/a        |      |                                                                           |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------|---------------------------------------------------------------------------|
| IA/0004/G | This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) B.II.f.1.e - Stability of FP - Change to an approved stability protocol                      | 01/06/2023   | n/a        |      |                                                                           |
| II/0001/G | This was an application for a group of variations. B.II.d.1.e - Change in the specification parameters and/or limits of the finished product - Change outside the approved specifications limits range B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data) | 12/05/2023   | 20/06/2024 | SmPC | The SmPC section 6.3 has been updated as follows: Shelf- life (30 months) |